46.02

2.63% -1.245

After Hours: 45.85 -0.17 -0.37%

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $46.02, with a volume of 927.01K. It is down -2.63% in the last 24 hours and down -4.26% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Previous Close:

$47.27

Open:

$46.77

24h Volume:

927.01K

Relative Volume:

1.10

Market Cap:

$2.58B

Revenue:

$665.13M

Net Income/Loss:

$64.50M

P/E Ratio:

40.22

EPS:

1.1442

Net Cash Flow:

$185.87M

1W Performance:

-16.52%

1M Performance:

-4.26%

6M Performance:

+48.74%

1Y Performance:

+26.43%

1-Day Range:

$45.82

$47.48

1-Week Range:

$43.11

$57.40

52-Week Range:

$29.16

$57.65

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1134)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

674

Twitter

@Supernus_Pharma

Next Earnings Date

2024-11-04

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	46.02	2.70B	665.13M	64.50M	185.87M	1.1442
ZTS Zoetis Inc	120.24	52.69B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	13.66	43.09B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.46	41.90B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	23.97	28.06B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	448.91	19.55B	3.08B	1.24B	1.07B	25.61

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

03:55 AM

Is Supernus Pharmaceuticals Inc. a candidate for recovery play2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com

03:55 AM

Nov 08, 2025

The Technical Signals Behind (SUPN) That Institutions Follow - news.stocktradersdaily.com

Nov 08, 2025

Nov 07, 2025